New hope for breast cancer patients when first treatments fail
NCT ID NCT05675579
Summary
This study is testing whether a combination of two drugs, sacituzumab govitecan and pembrolizumab, can help control early-stage triple-negative breast cancer when given before surgery. It is for patients whose cancer did not shrink after receiving a standard initial treatment of chemotherapy plus immunotherapy. The goal is to see if this new approach can eliminate more cancer cells before surgery and improve long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.